Orphazyme confirms delisting in the US
After market closing on Thursday, there will be no more trading of Danish biotech firm Orphazyme’s secondary shares in the US, the company reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme files for delisting in US
For subscribers